Learning Objectives
- Explain the rationale behind IV-first vs IO-first vascular access strategies in out-of-hospital cardiac arrest
- Summarize the design and key findings of the PARAMEDIC-3 trial (NEJM, 2024)
- Identify what the trial found regarding time to drug administration and survival outcomes
- Apply the trial's findings to first-line vascular access decisions in cardiac arrest
Why Are We Talking About This?
In cardiac arrest, getting drugs on board fast matters. Epinephrine, amiodarone, whatever your protocol calls for. None of it works if it's not in the patient.
IV access in a coding patient is hard. Collapsed veins, poor perfusion, a moving rig, a crew already managing airway and compressions. IO looked like the fix. Drill it, push the drug, move on.
Observational data leaned toward IO being faster and easier. But that data has a flaw. IO usually gets used as a rescue line after a failed IV attempt. Those patients were already harder access, already losing time. Comparing IO outcomes to IV outcomes in that setup isn't a fair fight. It's confounded from the start.
To get a real answer, you have to randomize IV-first against IO-first as the initial strategy, not the backup. That's what PARAMEDIC-3 set out to do.
PARAMEDIC-3 Trial: What They Did
This was a pragmatic, open-label randomized controlled trial conducted across 11 emergency medical systems in the United Kingdom. Adult patients with out-of-hospital cardiac arrest who required vascular access were randomized to one of two first-line strategies:
| Group | Strategy |
|---|---|
| IV-First | Attempt intravenous access first |
| IO-First | Attempt intraosseous access first |
Primary outcome: survival at 30 days. Planned enrollment was 15,000. Funding ran out before the first interim analysis, and the trial closed early at 6,096 of 10,723 screened patients. Most exclusions happened because a non-study paramedic got IV access before randomization could occur. Primary outcome data was available for 99.7% of enrolled patients.
What They Found
| Outcome | IO-First | IV-First |
|---|---|---|
| 30-Day Survival | 4.5% | 5.1% |
| Favorable Neuro Outcome at Discharge | 2.7% | 2.8% |
| ROSC (Any Time) | 36.0% | 39.1% |
| Time to Vascular Access | 12 minutes | 12 minutes |
| Time to Drug Administration | 14 minutes | 14 minutes |
Time intervals were essentially identical. IO didn't get drugs on board any faster than IV, which is the assumption most providers carry into the field. Survival and ROSC were close between groups, and neither difference reached statistical significance.
What This Actually Means
Before you write off IO, let's think about the data. This trial doesn't say IO is inferior. It says IO-first didn't outperform IV-first. Two different findings. It also stopped early, enrolling about 6,100 of a planned 15,000 patients, so it wasn't powered to catch a small difference either way.
IO still has a place. You still need access, and IO gets you there when a vein won't cooperate.
Keep the priority straight. Compressions keep this patient alive. Access matters, but never at the cost of compression quality or fraction.
What This Study Supports
IV first, IO ready as backup, is a reasonable plan in cardiac arrest.
What This Study Doesn't Prove
That IO is inferior to IV, or that either strategy guarantees faster access in every patient.
Apply What You Know
You arrive to find a 58-year-old male in cardiac arrest. Bystander CPR is in progress. Your partner takes over compressions while you set up for airway and access. The patient has a history of IV drug use and poor peripheral veins are immediately obvious on exposure.
You have both IV and IO capability on your unit. Your partner asks what you want to try first for access.
Based on the PARAMEDIC-3 trial, what is your first-line approach?
I'm a big fan of IO access in arrest patients. It gives us another tool during a critical time. I think it's reasonable to try twice for a line and prep for the IO if those attempts fail.